New hope for kids with inoperable brain cancer: targeted radiation trial seeks safer dose
NCT ID NCT05610891
Summary
This early-stage study is testing a new targeted radiation drug called CLR 131 in children and young adults (ages 10-25) with aggressive brain tumors that have returned or not responded to other treatments and cannot be removed by surgery. The main goals are to find a safe and effective dose and to see if the treatment can help control the cancer and extend life. Researchers will closely monitor how the body handles the drug and track any side effects and changes in tumor size.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Stanford University
Palo Alto, California, 94304, United States
-
Texas Children's Cancer Center, Baylor College of Medicine
Houston, Texas, 77030, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
-
University of Wisconsin, Carbone Cancer Center
Madison, Wisconsin, 53705, United States
Conditions
Explore the condition pages connected to this study.